KIT and systemic mastocytosis: Patients who are diagnosed with well-differentiated SM (WDSM) may also benefit from imatinib treatment because WDSM is associated with lower frequencies of KIT mutations involving the activation loop, such as the imatinib-resistant D816V KIT mutation, compared with patients with advanced SM (26).